Share on StockTwits
 

Equities researchers at Credit Suisse hoisted their price objective on shares of BioMarin Pharmaceutical (NYSE:BMRN) from $68.00 to $73.00 in a research report issued on Wednesday, StockRatingsNetwork reports. Credit Suisse’s price target would suggest a potential downside of 4.44% from the stock’s previous close.

BMRN has been the subject of a number of other recent research reports. Analysts at Jefferies Group raised their price target on shares of BioMarin Pharmaceutical from $83.00 to $87.00 in a research note on Wednesday. Separately, analysts at Wedbush raised their price target on shares of BioMarin Pharmaceutical from $72.00 to $74.00 in a research note on Tuesday. Finally, analysts at Barclays downgraded shares of BioMarin Pharmaceutical from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. They now have a $73.00 price target on the stock, down previously from $75.00. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $77.00.

BioMarin Pharmaceutical (NYSE:BMRN) traded down 0.05% during mid-day trading on Wednesday, hitting $76.35. 1,269,120 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a 1-year low of $53.14 and a 1-year high of $80.67. The stock’s 50-day moving average is $70.57 and its 200-day moving average is $68.82. The company’s market cap is $10.858 billion.

BioMarin Pharmaceutical Inc (NYSE:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.